Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: Brain Behav Immun. 2008 Oct 4;23(2):240–250. doi: 10.1016/j.bbi.2008.09.012

Figure 3. AV411 prevents spontaneous morphine and oxycodone withdrawal induced weight loss.

Figure 3

AV411 (7.5mg/kg twice daily) protects against morphine (A; ■) and oxycodone (B; ◆) induced weight loss when compared to morphine (■) or oxycodone (◆) plus vehicle treated rats. It appears that these weight loss effects are likely due to the opioid withdrawal, since AV411+saline rats do not show such weight loss (○). Data are expressed as the change in weight after the start of spontaneous withdrawal, compared to weight just prior to the initiation of spontaneous withdrawal. A two-way ANOVA with Bonferroni post hoc analysis revealed significant differences between AV411 and vehicle treated rats just one day after withdrawal that continued thought the rest of the observation (day 15 to day 26; P<0.05). n=6-9/group.